Naemura David H.
Naemura David H.'s purchase track record
How the stock did after each of Naemura David H.'s open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 1/16/2025 | NEOG | $164K | -62.2% | -58.1% | +6.1% |
| 4/10/2024 | NEOG | $156K | +21.4% | +18.8% | +12.2% |
| 10/11/2023 | NEOG | $150K | +25.3% | -16.5% | +17.9% |
| 3/7/2022 | VNT | $194K | +19.7% | -6.8% | -7.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Diebold Nixdorf partners stc pay Bahrain on digital‑physical services. Diebold Nixdorf announced a partnership with stc pay Bahrain to connect digital payment solutions with its physical financial service offerings. The collaboration aims to broaden the company’s reach in the Middle East by combining stc pay’s mobile platform with Diebold Nixdorf’s ATM and kiosk network. The firm also scheduled its 2026 third‑quarter investor call for Oct. 28, giving analysts an opportunity to discuss progress on converting its order backlog into cash.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Vontier Unveils Mobility Platform, Expands Food Aid Program. Vontier announced the launch of Vantage Point, a new platform that aggregates mobility data to help businesses optimize transportation. The company also extended its partnership with the NACS Foundation’s Neighborhood Nourish Program, aiming to address food insecurity in communities. Analysts have highlighted the company’s solid fundamentals and noted potential upside, reflecting growing confidence in its strategic initiatives.
Transaction History
| NEOG | ▲ Buy | Option Exercise | 12,912 | $77K | 12/1/2025 | View on chart |
| NEOG | ▼ Sell | Tax Withholding | 3,548 | $21K | 12/1/2025 | View on chart |
| NEOG | ▲ Buy | Option Exercise | 15,504 | $96K | 10/27/2025 | View on chart |
| NEOG | ▼ Sell | Tax Withholding | 4,261 | $26K | 10/27/2025 | View on chart |
| NEOG | ▲ Buy | Option Exercise | 14,294 | $78K | 8/18/2025 | View on chart |
| NEOG | ▼ Sell | Tax Withholding | 5,947 | $32K | 8/18/2025 | View on chart |
| NEOG | ▲ Buy | Grant | 230,203 | $1.3M | 8/15/2025 | View on chart |
| NEOG | ▲ Buy | Grant | 52,724 | $300K | 6/2/2025 | View on chart |
| NEOG | ▲ Buy | Grant | 10,034 | $116K | 1/16/2025 | View on chart |
| NEOG | ▲ Buy | Open Market | 14,800 | $164K | 1/16/2025 | View on chart |
| NEOG | ▲ Buy | Option Exercise | 12,911 | $183K | 11/29/2024 | View on chart |
| NEOG | ▼ Sell | Tax Withholding | 5,371 | $76K | 11/29/2024 | View on chart |
| NEOG | ▲ Buy | Option Exercise | 15,504 | $214K | 10/28/2024 | View on chart |
| NEOG | ▼ Sell | Tax Withholding | 6,450 | $89K | 10/28/2024 | View on chart |
| NEOG | ▲ Buy | Grant | 42,883 | $720K | 8/15/2024 | View on chart |
| NEOG | ▲ Buy | Open Market | 12,500 | $156K | 4/10/2024 | View on chart |
| DBD | ▲ Buy | Grant | 40,000 | $0 | 12/24/2023 | View on chart |
| NEOG | ▲ Buy | Open Market | 10,000 | $150K | 10/11/2023 | View on chart |
| VNT | ▲ Buy | Open Market | 8,500 | $194K | 3/7/2022 | View on chart |
| VNT | ▲ Buy | Grant | 33,035 | $0 | 2/28/2022 | View on chart |
| VNT | ▼ Sell | Tax Withholding | 3,924 | $95K | 2/25/2022 | View on chart |
| VNT | ▼ Sell | Tax Withholding | 15,756 | $386K | 2/18/2022 | View on chart |
| VNT | ▼ Sell | Tax Withholding | 1,344 | $41K | 12/15/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Neogen Corp reports earnings, faces FDA warning, outlines growth plan
Neogen released its 2027 Q1 earnings presentation, highlighting recent revenue trends and upcoming initiatives. The company also disclosed an FDA warning related to a contaminated veterinary product, which may affect short‑term perception. At its recent Investor Day, management outlined a plan to reach a 30% EBITDA margin by 2031 and emphasized growing demand for food‑safety solutions. Analysts continue to note the stock’s recent price movement amid these developments.
Neogen Corp reports earnings, faces FDA warning, outlines growth plan. Neogen released its 2027 Q1 earnings presentation, highlighting recent revenue trends and upcoming initiatives. The company also disclosed an FDA warning related to a contaminated veterinary product, which may affect short‑term perception. At its recent Investor Day, management outlined a plan to reach a 30% EBITDA margin by 2031 and emphasized growing demand for food‑safety solutions. Analysts continue to note the stock’s recent price movement amid these developments.